SOBIS Stock Overview
An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Swedish Orphan Biovitrum AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 334.20 |
| 52 Week High | SEK 344.80 |
| 52 Week Low | SEK 256.90 |
| Beta | 0.26 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 35.14% |
| 3 Year Change | 73.75% |
| 5 Year Change | 104.53% |
| Change since IPO | 877.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| SOBIS | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -4.9% | -0.9% |
| 1Y | 35.1% | -16.3% | 9.8% |
Return vs Industry: SOBIS exceeded the UK Biotechs industry which returned -16.3% over the past year.
Return vs Market: SOBIS exceeded the UK Market which returned 9.8% over the past year.
Price Volatility
| SOBIS volatility | |
|---|---|
| SOBIS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: SOBIS's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine SOBIS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1939 | 1,840 | Guido Oelkers | www.sobi.com |
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra.
Swedish Orphan Biovitrum AB (publ) Fundamentals Summary
| SOBIS fundamental statistics | |
|---|---|
| Market cap | SEK 107.29b |
| Earnings (TTM) | SEK 3.89b |
| Revenue (TTM) | SEK 26.03b |
27.6x
P/E Ratio4.1x
P/S RatioIs SOBIS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SOBIS income statement (TTM) | |
|---|---|
| Revenue | SEK 26.03b |
| Cost of Revenue | SEK 5.70b |
| Gross Profit | SEK 20.33b |
| Other Expenses | SEK 16.44b |
| Earnings | SEK 3.89b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Mar 31, 2025
| Earnings per share (EPS) | 11.31 |
| Gross Margin | 78.09% |
| Net Profit Margin | 14.93% |
| Debt/Equity Ratio | 40.5% |
How did SOBIS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/22 07:50 |
| End of Day Share Price | 2025/01/23 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Swedish Orphan Biovitrum AB (publ) is covered by 29 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Shirley Chen | Barclays |
| Rosie Turner | Barclays |